Abstract: Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein

Abstract: A heat shrink apparatus for heat shrinking a shrink film to a bladder. The heat shrink apparatus may include a support structure, a bladder support system, and a heat chamber. The bladder support system for supporting the bladder thereon may have two spaced apart parallel rows of a plurality of resilient members pivotally and/or resiliently attached to the support structure. The heat chamber may be hollow with opposing end openings and may have one or more heating elements therein. The heat chamber may translate over the shrink film and the bladder along the support structure between the two spaced apart parallel rows, shrinking the shrink film to the bladder. As the heat chamber translates, it may contact ends of the resilient members, thereby pivoting or deflecting the resilient members from a first position to a second position such that the heat chamber can pass between the two parallel rows.

Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Abstract: A vehicle pillar assembly is provided which includes a roof rail, a rocker, a first hollow support member, and a second hollow support member. The first hollow support member and the second hollow support member each includes a first wall, a second wall, a third wall and optionally a fourth wall. The first hollow support member and the second hollow support member each include a tubular lower area that extends upwardly from the rocker panel. The tubular lower area includes at least one crush initiator. The first hollow support member and the second hollow support member also each include an upper section that extends downwardly from the roof rail.

Abstract: Compounds having the formula I wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Abstract: A die for forming an elongated strand of continuous material includes a front surface, an opposing back surface, a peripheral surface positioned therebetween, a groove, and a pair of peaks. The groove may be located on the front surface and may originate near the center of the front surface and terminate at the edge of the front surface. The groove may revolve around the center, getting progressively farther away from the center as it revolves. The peaks may be located at opposing edges of the groove, wherein the peaks of one portion of the groove contact the peaks of neighboring portions of the groove to form a blade. The die is pressed against an adhesive charge, such that the blade cuts the material to form an elongated, continuous noodle.

Abstract: Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Abstract: A vehicle roof support assembly is provided which includes a roof rail, a rocker panel, a first hollow support member and a second hollow support member. The first hollow support member and the second hollow support member each includes an inner wall, an outer wall, a front wall, a front wall and a rear wall. The first hollow support member and the second hollow support member each include a tubular lower area that extends upwardly from the rocker panel. The first hollow support member and the second hollow support member also each include an upper section that extends downwardly from the roof rail. The first hollow support member and the second hollow support member are spaced apart from one another in at least a middle area of the first and second hollow support members.

Abstract: Compounds having the formula I wherein R1, R2, R3, R4a, R4b, R4c, R5, R6, R9 and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Abstract: This application discloses compounds of generic Formula I: or pharmaceutically acceptable salts thereof, wherein A, R1, R2, R3, R4, Q, X, Y, m, p, and q are defined as described herein, useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Abstract: Compounds having the formula I wherein A, R1, R2, R3, R4a, R4b, R4c, R5, R6, R7a, R7b, Ar1, Rc, Rd, Re, Rf, X, n and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Abstract: Compounds having the formula I wherein R1, R2, R3, R4, and R5 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Abstract: Compounds having the formula I wherein R1, R2, R3, R4, R5a, R5b, R5c and R6 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Abstract: Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Abstract: Compounds having the formula I wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Abstract: This application discloses aminopiperidinyl compounds of generic Formulae I-II: or pharmaceutically acceptable salts thereof, wherein m, r, Q1, Q2, Q3, R, Ra, R1, R2a, R2b, and R3 are defined as described herein, useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Abstract: Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Abstract: Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein

Abstract: Compounds having the formula I wherein R1, R2, R3, R4, and R5 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Abstract: Compounds having the formula I wherein wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.